Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice

Breast Cancer Research and Treatment

Volumn 133, Issue 2, 2012, Pages 523-536

  Ottewell, Penelope D ^a   Brown, Hannah K ^a   Jones, Mark ^a   Rogers, Thea L ^a   Cross, Simon S ^a   Brown, Nicola J ^b   Coleman, Robert E ^a   Holen, Ingunn ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bisphosphonates; Breast cancer; Doxorubicin; PyMT MMTV FVB; Zoledronic acid

Indexed keywords

DOXORUBICIN; ZOLEDRONIC ACID;

ACINAR CELL; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST ADENOCARCINOMA; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STAGING; CARCINOGENESIS; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; IMMUNOCOMPETENCE; MACROPHAGE; MONOTHERAPY; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CELL PROLIFERATION; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOXORUBICIN; FEMALE; IMIDAZOLES; IMMUNOCOMPETENCE; MACROPHAGES; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84863717286     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1782-x     Document Type: Article

References (49)

1. Costa L, Harper P, Coleman RE, Lipton A (2011) Anticancer evidence for zoledronic acid across the cancer continuum. Crit Rev Oncol Hematol 77(Suppl 1):S31-S37
2. Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264(1):108-111
3. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15(8):1467-1476
4. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296(2):235-242
5. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88(12 Suppl):2961-2978
6. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ (2001) Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28(5):465-473
7. Lee MV, Fong EM, Singer FR, Guenette RS (2001) Bisphosph-onate treatment inhibits the growth of prostate cancer cells. Cancer Res 61(6):2602-2608
8. Shipman CM, Rogers MJ, Apperley JF, Russell RG, Croucher PI (1997) Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 98(3):665-672
9. Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82(8):1459-1468
10. van der Pluijm G, Vloedgraven H, van Beek E, van der Wee-Pals L, Lowik C, Papapoulos S (1996) Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. J Clin Invest 98(3):698-705
11. Boissier S, Magnetto S, Frappart L, Cuzin B, Ebetino FH, Delmas PD, Clezardin P (1997) Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res 57(18):3890-3894
12. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM, Clézardin P (2000) Bis-phosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60(11):2949-2954
13. Basi DL, Lee SW, Helfman S, Mariash A, Lunos SA (2010) Accumulation of VEGFR2 in zoledronic acid-treated endothelial cells. Mol Med Report 3(3):399-403
14. Green JR, Guenther A (2011) The backbone of progress-pre-clinical studies and innovations with zoledronic acid. Crit Rev Oncol Hematol 77(Suppl 1):S3-S12
15. Brown HK, Ottewell PD, Coleman RE, Holen I (2011) The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells. J Cell Mol Med 15(3):501-513
16. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10(13):4559-4567
17. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL (2003) Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9(1):295-306
18. Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, Weil-baecher K (2005) HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition. Blood 106(13):4294-4302
19. Croucher PI, De Hendrik R, Perry MJ, Hijzen A, Shipman CM, Lippitt J, Green J, Van Marck E, Van Camp B, Vanderkerken K (2003) Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival. J Bone Miner Res 18(3):482-492
20. Kim SJ, Uehara H, Yazici S, He J, Langley RR, Mathew P, Fan D, Fidler IJ (2005) Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer. Cancer Res 65(9):3707-3715
21. Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F, Redini F (2005) Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37(1):74-86
22. Hiraga T, Ueda A, Tamura D, Hata K, Ikeda F, Williams PJ, Yoneda T (2003) Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. Int J Cancer 106(6):973-979
23. Melisi D, Caputo R, Damiano V, Bianco R, Veneziani BM, Bianco AR, De Placido S, Ciardiello F, Tortora G (2005) Zoled-ronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 12(4):1051-1058
24. Zhou Z, Guan H, Duan X, Kleinerman ES (2005) Zoledronic acid inhibits primary bone tumor growth in Ewing sarcoma. Cancer 104(8):1713-1720
25. Segawa H, Kimura S, Kuroda J, Sato K, Yokota A, Kawata E, Kamitsuji Y, Ashihara E, Yuasa T, Fujiyama Y, Ottmann OG, Maekawa T (2005) Zoledronate synergises with imatinib mesy-late to inhibit Ph primary leukaemic cell growth. Br J Haematol 130(4):558-560
26. Suva LJ (2010) Adjuvant bisphosphonates in breast cancer: the ABCSG-12 study. Curr Osteoporos Rep 8(2):57-59
27. Coleman RE (2011) Is caring for bone also fighting the breast cancer? Breast 20(Suppl 1):S2
28. Ottewell PD, Deux B, Mönkkönen H, Cross S, Coleman RE, Clezardin P, Holen I (2008) Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 14(14):4658-4666
29. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I (2008) Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 100(16):1167-1178
30. Ottewell PD, Lefley DV, Cross SS, Evans CA, Coleman RE, Holen I (2010) Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxoru-bicin and zoledronic acid in a breast cancer model. Int J Cancer 126(2):522-532
31. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW (2003) Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 163(5):2113-2126
32. Qiu TH, Chandramouli GV, Hunter KW, Alkharouf NW, Green JE, Liu ET (2004) Global expression profiling identifies signatures of tumor virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res 64(17):5973-5981
33. Wang S, Yuan Y, Liao L, Kuang SQ, Tien JC, O'Malley BW, Xu J (2009) Disruption of the SRC-1 gene in mice suppresses breast cancer metastasis without affecting primary tumor formation. Proc Natl Acad Sci USA 106(1):151-156
34. Ritland SR, Rowse GJ, Chang Y, Gendler SJ (1997) Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. Cancer Res 57(16):3520-3525
35. Kyle AH, Huxham LA, Baker JH, Burston HE, Minchinton AI (2003) Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent. Cancer Res 63(18):5707-5711
36. Marshman E, Ottewell PD, Potten CS, Watson AJ (2001) Caspase activation during spontaneous and radiation-induced apoptosis in the murine intestine. J Pathol 195(3):285-292
37. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76-85
38. Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphospho-nate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114(5):623-633
39. Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E (2007) Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochem Pharmacol 74(2):191-201
40. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I (2009) Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 8(10):2821-2832
41. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW (2006) Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 66(23):11238-11246
42. Neville-Webbe HL, Rostami-Hodjegan A, Evans CA, Coleman RE, Holen I (2005) Sequence-and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubi-cin in breast and prostate cancer cells. Int J Cancer 113(3): 364-371
43. Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA (1994) Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol Pharmacol 45(4):649-656
44. Fornari FA Jr, Jarvis WD, Grant S, Orr MS, Randolph JK, White FK, Mumaw VR, Lovings ET, Freeman RH, Gewirtz DA (1994) Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Differ 5(7):723-733
45. Winter MC, Evans A, Holen I, Coleman RE (2010) Exploring the anti-angiogenic potential of zoledronic acid in combination with neoadjuvant chemotherapy in invasive breast cancer. Bone 47(Suppl 2):S310-S310
46. Lynn KD, Udugamasooriya DG, Roland CL, Castrillon DH, Kodadek TJ, Brekken RA (2010) GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer 10:397
47. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M (2010) Zoledronic acid repolar-izes tumour-associated macrophages and inhibits mammary car-cinogenesis by targeting the mevalonate pathway. J Cell Mol Med 14(12):2803-2815
48. Woodward JK, Neville-Webbe HL, Coleman RE, Holen I (2005) Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs 16(8):845-854
49. Thompson K, Rogers MJ, Coxon FP, Crockett JC (2006) Cyto-solic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 69(5): 1624-1632